Cargando…
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
PURPOSE: People with pre-existing conditions may be more susceptible to severe COVID-19 when infected by SARS-CoV-2. The relative risk and severity of SARS-CoV-2 infection in people with rare diseases such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), or schwannomatosis (SWN) is...
Autores principales: | Banerjee, Jineta, Friedman, Jan M., Klesse, Laura J., Yohay, Kaleb H., Jordan, Justin T., Plotkin, Scott R., Allaway, Robert J., Blakeley, Jaishri O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579183/ https://www.ncbi.nlm.nih.gov/pubmed/36565307 http://dx.doi.org/10.1016/j.gim.2022.10.007 |
Ejemplares similares
-
Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis
por: Fayad, Laura M., et al.
Publicado: (2013) -
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
por: Merker, Vanessa L., et al.
Publicado: (2022) -
The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020) -
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
por: Merker, Vanessa L., et al.
Publicado: (2018) -
Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis
por: Tamura, Ryota
Publicado: (2021)